NDAINTRAVENOUSINJECTABLE
Approved
Mar 2001
Lifecycle
LOE Approaching
Competitive Pressure
35/100
Clinical Trials
6
Data completeness
4/8 — Partial
PROTONIX IV (pantoprazole sodium) by Pfizer is 12. First approved in 2001.
Drug data last refreshed 4h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROTONIX IV is a proton pump inhibitor (PPI) containing pantoprazole sodium for intravenous administration. It suppresses gastric acid secretion by covalently binding to the H+/K+-ATPase enzyme on gastric parietal cells, providing antisecretory effects lasting over 24 hours. It is indicated for patients with gastroesophageal reflux disease (GERD) and erosive esophagitis who cannot take oral medication.
$0.024BPart D
LOE ApproachingDeclining
11mo to LOEProduct is in late decline with minimal Part D utilization; commercial team is likely focused on managed care retention and hospital formulary defense.
Mechanism of Action
12.1 Mechanism of Action Pantoprazole is a PPI that suppresses the final step in gastric acid production by covalently binding to the (H, K)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid…
Worked on PROTONIX IV at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.